OTC Markets OTCPK - Delayed Quote USD

Takeda Pharmaceutical Company Limited (TKPHF)

42.00 +4.03 (+10.61%)

At close: October 30 at 4:00:00 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading

PREMIUM
MT Newswires 3d ago

ASX

TAK

TC
What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call

MarketBeat 3d ago

TAK
Takeda (TAK) Q2 2026 Earnings Call Transcript

Motley Fool 4d ago

TAK
Takeda H1 profit rises on cost savings, currency gains; hikes FY outlook

Investing.com 4d ago

TAK

4502
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones

Business Wire 4d ago

TAK
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

PR Newswire 8d ago

1801.HK

TAK
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

Business Wire 10d ago

TAK
Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage

MarketBeat 11d ago

KROS

TAK
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading

PREMIUM
MT Newswires 11d ago

TME

TAK

ASX
Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of Directors

Exec Edge 13d ago

PFE

NVS

JCI
Disease Clearance Data Might Change The Case For Investing In Takeda (TSE:4502)

Simply Wall St. 13d ago

TAK

4502
Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

PREMIUM
MT Newswires 13d ago

TC

TAK

SIMO

Performance Overview

Return	TKPHF	Nikkei 225 (^N225)
YTD	+40.43%	+25.31%
1-Year	+56.99%	+20.36%
3-Year	+80.24%	+97.44%

U.S. markets closed

Takeda Pharmaceutical Company Limited (TKPHF)

Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading

What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call

Takeda (TAK) Q2 2026 Earnings Call Transcript

Takeda H1 profit rises on cost savings, currency gains; hikes FY outlook

Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones

2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage

Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading

Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of Directors

Disease Clearance Data Might Change The Case For Investing In Takeda (TSE:4502)

Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading